<DOC>
	<DOCNO>NCT01682902</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial evaluate continuous subcutaneous infusion NN1218 formulation NovoLog® subject type 1 diabetes .</brief_summary>
	<brief_title>A Randomised Trial Evaluating Continuous Subcutaneous Infusion Formulations NN1218 NovoLog® Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 1 diabetes mellitus ( diagnose clinically ) least 12 month prior screen visit ( Visit 1 ) Treatment insulin analogue CSII ( continuous subcutaneous insulin infusion ) previous 3 month prior screen visit ( Visit 1 ) Using MiniMed Paradigm® pump ( 515/715 , 522/722 523/723 ) previous 6 month prior screen visit ( Visit 1 ) Glycosylated haemoglobin ( HbA1c ) equal 9.0 % central laboratory Body Mass Index ( BMI ) equal 35.0 kg/m^2 History diabetic ketoacidsosis ( DKA ) episodes require hospitalization within 6 month prior screen visit ( Visit 1 ) History abscess infusion site within 6 month prior screen visit ( Visit 1 ) Hypoglycaemic unawareness judge Investigator history severe hypoglycaemic episode require hospitalization within last 6 month prior screen visit ( Visit 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>